New Norvey: Luncanaizhu Monoclonal Antibody Injection Approved for Clinical Trials.

New Notice of Nuowei, holding subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the approval of the injection solution of Lunakenumab. The drug will soon begin clinical trials. Lunakenumab injection is a recombinant anti-human -amyloid monoclonal antibody drug, a biosimilar of Elelyso, which is used to treat mild cognitive impairment and mild dementia caused by Alzheimer's disease.